Pfizer Japan Surveys Doctors on Blood Pressure Control.Tokyo, Japan, Nov 9, 2005 - (JCNN JCNN Japan Corporate News Network ) - Pfizer Japan announced the results on November 8th of its latest online survey of medical professionals on blood pressure control. With the aid of ACNielsen Japan, the company surveyed 472 doctors aged 40 or older who are currently taking antihypertensives, from August 6 to September 5. Of the respondents In the context of marketing research, a representative sample drawn from a larger population of people from whom information is collected and used to develop or confirm marketing strategy. , 24.2% take Norvasc by Pfizer, followed by Blopress by Takeda Pharmaceutical (16.7%) and Diovan by Novartis Pharma (16.3%). When asked about the reason why they choose Norvasc, 82.5% mentioned that the agent can exert an effect when it is used as a sole regimen regimen /reg·i·men/ (rej´i-men) a strictly regulated scheme of diet, exercise, or other activity designed to achieve certain ends. reg·i·men n. 1. . Also, 62.3% cited its long-lasting effect, namely the agent remains effective for 24 hours Adv. 1. for 24 hours - without stopping; "she worked around the clock" around the clock, round the clock with a single administration, and 42.1% relied on the acknowledged evidence. Of the respondents, 46.0% said that antihypertensives meet their targets of blood pressure control, and the remaining 54.0% confessed that they do not meet the criteria. Still, of those who have failed in blood pressure control, 83.2% believe that they control their blood pressure to a certain extent. Regarding measuring blood pressure, only 34.1% of the respondents said that they check their blood pressure more than once a day, while 22.9% once in two or three days and 21.8% once a week. A calcium antagonist antagonist /an·tag·o·nist/ (an-tag´o-nist) 1. a substance that tends to nullify the action of another, as a drug that binds to a cell receptor without eliciting a biological response, blocking binding of substances that could initially released in the UK in 1991, Norvasc has been available in Japan since 1993. Worldwide sales of Norvasc reached $4.46 billion in fiscal 2004. Source: JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) http://www.japancorp.net Copyright [c] 2005 Japan Corporate News Network. All rights reserved. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion